Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talampanel in Recurrent High-Grade Gliomas
NCT00062504Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of talampanel in high-grade glioma (HGG) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: 6-month Progression Free Survival. Started Jul 2003; status: terminated.
02
Drugs
talampanel
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00062504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062504.